| Literature DB >> 33075858 |
Sun Young Lee1,2, Kyoung Jun Song2,3, Chun Soo Lim4, Byeong Gwan Kim5, Young Jun Chai6, Jung Kyu Lee7, Su Hwan Kim5, Hyouk Jae Lim2,8.
Abstract
BACKGROUND: In response to the disaster of coronavirus disease 2019 (COVID-19) pandemic, Seoul Metropolitan Government (SMG) established a patient facility for mild condition patients other than hospital. This study was conducted to investigate the operation and necessary resources of a community treatment center (CTC) operated in Seoul, a metropolitan city with a population of 10 million.Entities:
Keywords: COVID-19; Community Treatment Center; Disaster; Surge Capacity
Mesh:
Year: 2020 PMID: 33075858 PMCID: PMC7572227 DOI: 10.3346/jkms.2020.35.e367
Source DB: PubMed Journal: J Korean Med Sci ISSN: 1011-8934 Impact factor: 2.153
Patients of Seoul metropolitan city and Seoul CTC
| Variables | Seoul metropolitan city | Seoul CTC | ||
|---|---|---|---|---|
| Total | Death, No. (%) | Admission, No. (%) | ||
| Total | 803 | 4 (0.5) | 213 (26.5) | |
| Sex | ||||
| Female | 383 | 0 (0.0) | 111 (29.0) | |
| Male | 420 | 4 (1.0) | 102 (24.3) | |
| Age, yr | ||||
| 0–9 | 11 | 0 (0.0) | 0 (0.0) | |
| 10–19 | 41 | 0 (0.0) | 8 (19.5) | |
| 20–29 | 268 | 0 (0.0) | 114 (42.5) | |
| 30–39 | 139 | 0 (0.0) | 42 (30.2) | |
| 40–49 | 116 | 1 (0.9) | 28 (24.1) | |
| 50–59 | 126 | 0 (0.0) | 21 (16.7) | |
| 60–69 | 57 | 1 (1.8) | 0 (0.0) | |
| 70–79 | 31 | 0 (0.0) | 0 (0.0) | |
| ≤ 80 | 14 | 2 (14.3) | 0 (0.0) | |
CTC = community treatment center.
Fig. 1Route of admission and discharge of Seoul CTC.
CTC = community treatment center.
a4 patients who did not have virologic remission until the closing of the Seoul CTC transferred to the hospital on May 27.
Fig. 2Trends of number of patients – Seoul CTC and Seoul metropolitan city.
CTC = community treatment center.
Patient characteristics by route of discharge
| Characteristics | Total, No. (%) | Hospital transfer, No. (%) | Home discharge, No. (%) | |
|---|---|---|---|---|
| Total | 213 (100.0) | 22 (100.0) | 191 (100.0) | |
| Sex | ||||
| Female | 111 (52.1) | 11 (50.0) | 100 (52.4) | |
| Male | 102 (47.9) | 11 (50.0) | 91 (47.6) | |
| Age, yr | ||||
| 10–19 | 8 (3.8) | 0 (0.0) | 8 (4.2) | |
| 20–29 | 114 (53.5) | 10 (45.5) | 104 (54.5) | |
| 30–39 | 42 (19.7) | 3 (13.6) | 39 (20.4) | |
| 40–49 | 28 (13.1) | 6 (27.3) | 22 (11.5) | |
| 50–59 | 21 (9.9) | 3 (13.6) | 18 (9.4) | |
| Median (IQR) | 28.0 (23.0–38.0) | 33.5 (23.0–46.0) | 28.0 (23.0–37.0) | |
| Length of stay, wk | ||||
| < 1 | 28 (13.1) | 11 (50.0) | 17 (8.9) | |
| 1–2 | 35 (16.4) | 2 (9.1) | 33 (17.3) | |
| 2–3 | 41 (19.2) | 4 (18.2) | 37 (19.4) | |
| 3–4 | 48 (22.5) | 1 (4.5) | 47 (24.6) | |
| 4–5 | 23 (10.8) | 1 (4.5) | 22 (11.5) | |
| 5–6 | 23 (10.8) | 1 (4.5) | 22 (11.5) | |
| 6–7 | 10 (4.7) | 0 (0.0) | 10 (5.2) | |
| 7–8 | 5 (2.3) | 2 (9.1) | 3 (1.6) | |
| Median (IQR) | 21.0 (12.0–29.0) | 7.5 (3.0–20.0) | 22.0 (13.0–30.0) | |
| Duration of diagnosis to admission, wk | ||||
| 0 | 101 (47.4) | 12 (54.5) | 89 (46.6) | |
| 1 | 52 (24.4) | 7 (31.8) | 45 (23.6) | |
| 2 | 25 (11.7) | 1 (4.5) | 24 (12.6) | |
| 3 | 20 (9.4) | 1 (4.5) | 19 (9.9) | |
| 4 | 8 (3.8) | 0 (0.0) | 8 (4.2) | |
| 5 | 2 (0.9) | 1 (4.5) | 1 (0.5) | |
| Unknown | 5 (2.3) | 0 (0.0) | 5 (2.6) | |
| Median (IQR) | 7.0 (0.0–14.0) | 5.5 (0.0–8.0) | 7.0 (0.0–15.0) | |
| Route of admission | ||||
| Hospital | 137 (64.3) | 13 (59.1) | 124 (64.9) | |
| Home | 75 (35.2) | 9 (40.9) | 66 (34.6) | |
| Other CTC | 1 (0.5) | 0 (0.0) | 1 (0.5) | |
| Symptom at admission | ||||
| Cough | 51 (23.9) | 6 (27.3) | 45 (23.6) | |
| Fever | 11 (5.2) | 2 (9.1) | 9 (4.7) | |
| Sputum | 44 (20.7) | 4 (18.2) | 40 (20.9) | |
| Rhinorrhea | 30 (14.1) | 1 (4.5) | 29 (15.2) | |
| Sore throat | 16 (7.5) | 2 (9.1) | 14 (7.3) | |
| Chest pain | 6 (2.8) | 2 (9.1) | 4 (2.1) | |
| Dyspnea | 2 (0.9) | 1 (4.5) | 1 (0.5) | |
| Othersa | 25 (11.7) | 4 (18.2) | 21 (11.0) | |
| Initial CXR | ||||
| Pneumonia suspicion | 19 (8.9) | 3 (13.6) | 16 (8.4) | |
| Nonspecific lesion | 18 (8.5) | 4 (18.2) | 14 (7.3) | |
| Normal | 167 (78.4) | 10 (45.5) | 157 (82.2) | |
| Not done | 9 (4.2) | 5 (22.7) | 4 (2.1) | |
| Medication use, median (IQR) | ||||
| Total | 3 (1–9) | 4 (1–8) | 3 (1–9) | |
| Per day | 0.2 (0.1–0.5) | 0.8 (0.4–1.2) | 0.2 (0.1–0.4) | |
IQR = interquartile range, CTC = community treatment center, CXR = chest X-ray.
aOthers: myalgia, general weakness, diarrhea, nausea, etc.
Weekly average number of consultation and test per day
| Weeks | Date | No. of patients | Patient consultation | Test | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Doctor | Psychiatric | Nurse | Total | Per patient | CXR | RT-PCR | Total | Per patient | |||
| 1 | 3/16–3/22 | 13.7 | 14.1 | 1.0 | 24.6 | 39.7 | 2.9 | 4.4 | 1.9 | 6.3 | 0.5 |
| 2 | 3/23–3/29 | 44.4 | 45.3 | 2.4 | 87.4 | 135.1 | 3.1 | 8.4 | 10.9 | 19.3 | 0.4 |
| 3 | 3/30–4/5 | 89.9 | 91.1 | 2.0 | 177.3 | 270.4 | 3.0 | 9.3 | 23.4 | 32.7 | 0.4 |
| 4 | 4/6–4/12 | 116.4 | 119.0 | 1.9 | 235.0 | 355.9 | 3.1 | 6.0 | 36.0 | 42.0 | 0.4 |
| 5 | 4/13–4/19 | 121.9 | 125.0 | 2.1 | 246.6 | 373.7 | 3.1 | 6.1 | 42.7 | 48.9 | 0.4 |
| 6 | 4/20–4/26 | 113.9 | 119.9 | 2.9 | 238.0 | 360.7 | 3.2 | 5.9 | 46.6 | 52.4 | 0.5 |
| 7 | 4/27–5/3 | 78.4 | 84.9 | 2.3 | 167.9 | 255.0 | 3.3 | 7.0 | 34.9 | 41.9 | 0.5 |
| 8 | 5/4–5/10 | 43.9 | 47.9 | 2.7 | 95.4 | 146.0 | 3.3 | 4.1 | 22.1 | 26.3 | 0.6 |
| 9 | 5/11–5/17 | 21.6 | 24.6 | 1.7 | 49.1 | 75.4 | 3.6 | 3.6 | 12.7 | 16.3 | 0.8 |
| 10 | 5/18–5/24 | 8.7 | 9.4 | 0.9 | 18.9 | 29.1 | 3.3 | 0.7 | 5.6 | 6.3 | 0.7 |
| 11 | 5/25–5/27 | 5.3 | 6.0 | 1.7 | 10.3 | 18.0 | 3.3 | 1.0 | 3.7 | 4.7 | 0.9 |
| Total | 3/16–5/24 | 65.3 | 68.1 | 2.0 | 134.0 | 204.1 | 3.2 | 5.6 | 23.7 | 29.2 | 0.5 |
CXR = chest X-ray, RT-PCR = reverse transcription polymerase chain reaction.
Frequent medication prescription of CTC
| No. | Symptoms | Medication (n = 1,990) | Values, No. (%) |
|---|---|---|---|
| 1 | Fever/pain control | Acetaminophen ERa | 389 (19.5) |
| 2 | Cough/sputum | Ambroxol | 230 (11.6) |
| 3 | Rhinorrhea | Pseudoephedrine/triprolidine | 178 (8.9) |
| 4 | Sleep problem | Melatonin | 163 (8.2) |
| 5 | Psychiatric | Trazodone HCl | 140 (7.0) |
| 6 | GI/Digestive | Famotidine | 132 (6.6) |
| 7 | Cough/sputum | Theobromine | 113 (5.7) |
| 8 | Rhinorrhea | Hydroxyzine HCl | 112 (5.6) |
| 9 | Psychiatric | Escitalopram | 103 (5.2) |
| 10 | Fever/pain control | Ibuprofen/arginin | 93 (4.7) |
| 11 | GI/digestive | Almagate | 89 (4.5) |
| 12 | Sputum | Erdosteine | 61 (3.1) |
| 13 | GI/digestive | Phazyme | 51 (2.6) |
| 14 | Etc | Chlorhexidine gluconate | 48 (2.4) |
| 15 | GI/digestive | Metoclopramide HCl | 25 (1.3) |
| 16 | GI/diarrhea | Dioctahedral smectite | 22 (1.1) |
| 17 | GI/constipation | Agio granule | 15 (0.8) |
| 18 | GI/digestive | Hyoscine-N-butylbromide | 10 (0.5) |
| 19 | GI/constipation | Magnesium oxide | 9 (0.5) |
| 20 | Etc | Mupirocin | 7 (0.4) |
CTC = community treatment center, GI = gastrointestinal.
aAcetaminophen was given to all patients at admission.